2025
COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
O'Connor C, Boyle A, Asfour L, Bhoyrul B, Bokhari L, Cotsarelis G, Cotter C, Craiglow B, Cutlar L, Dhurat R, Dlova N, Doche I, Donovan J, Drucker A, Eisman S, Melo D, Harries M, Hordinsky M, Kazmi A, King B, Kolios A, Meah N, Mirmirani P, Mostaghimi A, Ohyama M, Ovcharenko Y, Pirmez R, Piraccini B, Rudnicka L, Saceda‐Corralo D, Shapiro J, Sibbald C, Sinclair R, Smith B, Starace M, Vaño‐Galván S, Koh W, York K, McDonald I, Wall D. COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists. JEADV Clinical Practice 2025 DOI: 10.1002/jvc2.70067.Peer-Reviewed Original ResearchJanus kinase inhibitorsComplete blood countAlopecia areataSystemic therapySeverity of Alopecia ToolConventional systemic therapiesThyroid function testsComplete blood count testDermatology Life Quality IndexNon-scarring alopeciaLife Quality IndexLaboratory testsHair loss disorderHair specialistThrombophilia screeningLaboratory testing practicesCoagulation profileTreating AAHair expertsHepatitis BThyroid functionAutoimmune conditionsBlood countBlood testsKinase inhibitorsAutopsy: Infectious and Serious Communicable Diseases
Gill J, Brooks E. Autopsy: Infectious and Serious Communicable Diseases. 2025, 455-467. DOI: 10.1016/b978-0-443-21441-7.00021-2.Peer-Reviewed Original ResearchHuman immunodeficiency virusViral hepatitis BRisk of occupational infectionOccupational infectionInfection control practicesForensic autopsy populationImmunodeficiency virusHepatitis BInfectious disease testingTuberculosis infectionInfectious disease test resultsDiagnostic accuracyPostexposure managementInfectionSARS-CoV-2Autopsy populationAutopsyMicrobiological testsEbola virusPostmortem examinationDisease testingInfectious diseasesLaboratory personnelPreventive measuresDeath
2024
The Revised REACH-B Model Predicts Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
Mezzacappa C. The Revised REACH-B Model Predicts Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Gastroenterology 2024, 169: 173. PMID: 39622300, DOI: 10.1053/j.gastro.2024.11.017.Peer-Reviewed Original ResearchHepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among US Veterans With Chronic Hepatitis B
Wong R, Yang Z, Jou J, John B, Lim J, Cheung R. Hepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among US Veterans With Chronic Hepatitis B. Gastro Hep Advances 2024, 4: 100575. PMID: 39906477, PMCID: PMC11791144, DOI: 10.1016/j.gastha.2024.10.015.Peer-Reviewed Original ResearchChronic hepatitis B patientsChronic hepatitis BLiver-related outcomesHepatic decompensationHepatitis delta virusCohort of U.S. veteransNational cohortU.S. veteransRisk of cirrhosisIncidence of cirrhosisPositive patientsHDV infectionHepatitis BEvaluate incidenceHepatocellular carcinomaCirrhosisPatientsDecompensationVirus testingPropensity scoreHepatitisDelta virusNelson-Aalen methodDiagnosisOutcomesBH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists
O’Connor C, Asfour L, Bokhari L, Cotsarelis G, Cotter C, Craiglow B, Cutlar L, Dhurat R, Dlova N, Doche I, Donovan J, Eisman S, Melo D, Harries M, Hordinsky M, Kazmi A, King B, Meah N, Ohyama M, Ovcharenko J, Primez R, Piraccini B, Rudnicka L, Corralo D, Shapiro J, Sinclair R, Smith B, Starace M, Galvan S, Wang K, York K, McDonald I, Wall D. BH04 A global survey to assess practice of laboratory testing in alopecia areata by hair specialists. British Journal Of Dermatology 2024, 191: i74-i75. DOI: 10.1093/bjd/ljae090.151.Peer-Reviewed Original ResearchLiver function testsFunction testsHIV testingHepatitis BLipid testingAlopecia areataSeverity of Alopecia ToolScreening bloodHair disordersRenal function testsRisk of cardiovascular diseaseJanus kinase inhibitorsDermatology Life Quality IndexJanus kinaseBritish Association of DermatologistsLife Quality IndexLaboratory testsHair loss disorderSystemic therapyThyroid testsIdentification of comorbiditiesImmune-mediatedRenal functionThyroid diseaseAssociation of DermatologistsIdentification of hepatic steatosis among persons with and without HIV using natural language processing
Torgersen J, Skanderson M, Kidwai-Khan F, Carbonari D, Tate J, Park L, Bhattacharya D, Lim J, Taddei T, Justice A, Re V. Identification of hepatic steatosis among persons with and without HIV using natural language processing. Hepatology Communications 2024, 8: e0468. PMID: 38896066, PMCID: PMC11186806, DOI: 10.1097/hc9.0000000000000468.Peer-Reviewed Original ResearchConceptsImaging ReportingSteatotic liver diseaseHIV statusHepatic steatosisPrevalence of metabolic comorbiditiesImaging studiesVeterans Aging Cohort StudyCompare patient characteristicsPositive predictive valueAlcohol use disorderAging Cohort StudyIdentification of hepatic steatosisHIV infectionHepatitis BMetabolic comorbiditiesNatural language processing algorithmsRadiological studiesCohort studyPatient characteristicsClinical reviewLiver diseaseHIVPredictive valueUse disorderClinical image reportsHepatitis B
Khungar V, Han T. Hepatitis B. 2024, 227-235. DOI: 10.1201/9781003524489-36.Peer-Reviewed Original Researchvon Meyenburg complexes are more frequently associated with cholangiocarcinoma
Jain D, Khandakar B, Ni P, Kenney B, Qin L, Deshpande V, Fiel M. von Meyenburg complexes are more frequently associated with cholangiocarcinoma. Journal Of Clinical Pathology 2024, 78: 300-306. PMID: 38729770, DOI: 10.1136/jcp-2024-209572.Peer-Reviewed Original ResearchVon Meyenburg complexesHilar CCHepatic resectionCC casesChronic viral hepatitis BAssociated liver disordersMeyenburg complexesProgress to cholangiocarcinomaDysplasia/carcinoma in situMetastatic colon carcinomaViral hepatitis BCases of CCBile duct adenomaPolycystic kidney diseaseAssociated with cholangiocarcinomaBenign lesionsCryptogenic cirrhosisHepatitis BBiliary diseaseColon carcinomaMiscellaneous disordersKidney diseaseLiver diseaseCholangiocarcinomaLiver disordersAdvances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents
Lam R, Lim J. Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents. World Journal Of Hepatology 2024, 16: 331-343. PMID: 38577537, PMCID: PMC10989302, DOI: 10.4254/wjh.v16.i3.331.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsFunctional cure of chronic hepatitis BCure of chronic hepatitis BNovel investigational agentsChronic hepatitis BFunctional cureHepatitis B virusInvestigational agentsHepatitis BSuppression of HBV DNARisk of liver complicationsChronic hepatitis B virusAssociated with significant morbidityToll-like receptor agonistsOral nucleos(t)ide analoguesHepatitis B surface antigenB surface antigenLong-term treatmentAssociated with higher ratesMortality due to cirrhosisCheckpoint inhibitorsNucleos(t)ide analoguesVirologic suppressionPhase IIAntiviral regimensIII trialsPlasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure
Lu Y, Xin J, Liang X, Luo J, Li P, Zhou X, Yang H, Li J, Wang Y. Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure. The Journal Of Infectious Diseases 2024, 230: 957-969. PMID: 38373244, DOI: 10.1093/infdis/jiae079.Peer-Reviewed Original ResearchHBV-ACLF patientsChronic hepatitis BAcute-on-chronic liver failureMer tyrosine kinaseHBV-ACLFArea under the receiver operating characteristic curveNormal controlsLiver failureLiver cirrhosisHBV-related acute-on-chronic liver failurePrognosis of HBV-ACLFHepatitis B-related acute-on-chronic liver failureRisk stratification analysesReceiver operating characteristic curveCut-off valueShort-term mortalityPrognostic rolePrognostic significancePrognostic valueHepatitis BPoor prognosisMerTK expressionImmunohistochemistry stainingDiagnostic accuracyDisease progressionHepatitis B vaccine birth dose coverage among hepatitis B-exposed and hepatitis B-unexposed infants: evidence from the Healthy Beginning Initiative program in Benue State, Nigeria
Olakunde B, Itanyi I, Onyeka T, Paintsil E, Torpey K, Lasebikan N, Chigbu C, Ezeanolue E. Hepatitis B vaccine birth dose coverage among hepatitis B-exposed and hepatitis B-unexposed infants: evidence from the Healthy Beginning Initiative program in Benue State, Nigeria. Pan African Medical Journal 2024, 47: 67. PMID: 38681098, PMCID: PMC11055182, DOI: 10.11604/pamj.2024.47.67.40466.Peer-Reviewed Original ResearchHepB-BDAntenatal careInfants of mothersSecondary analysis of dataInstitutional deliveryHepB-BD coverageInitial programBirth dose coverageObstetric factorsSociodemographic characteristicsLess-educated mothersSecondary analysisControl of hepatitis BDose coverageAnalysis of dataPost-delivery surveysImmunization questionsHepatitis BHealthyCareHepBInfantsMothersHepatitisWomen
2023
1901. High Prevalence of Latent Tuberculosis Infection in a Malaysian Prison
Zhang L, Shenoi S, Kamarulzaman A, Dhaliwal S, Ahmad A, Altice F. 1901. High Prevalence of Latent Tuberculosis Infection in a Malaysian Prison. Open Forum Infectious Diseases 2023, 10: ofad500.1729. PMCID: PMC10677608, DOI: 10.1093/ofid/ofad500.1729.Peer-Reviewed Original ResearchLatent tuberculosis infectionPrevalence of LTBIRisk of LTBITB preventive therapyIndependent risk factorTuberculin skin testC-reactive proteinActive TBPreventive therapyTuberculosis infectionRisk factorsHigh prevalenceMultivariable logistic regressionOpioid use disorderRisk of hepatotoxicityChest X-rayDrug use historyPaucity of dataLTBI treatmentHCV infectionHepatitis CHepatitis BMedian ageBlood testsSkin testPrevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database
Gish R, Jacobson I, Lim J, Waters-Banker C, Kaushik A, Kim C, Cyhaniuk A, Wong R. Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database. Hepatology 2023, 79: 1117-1128. PMID: 37976395, PMCID: PMC11020024, DOI: 10.1097/hep.0000000000000687.Peer-Reviewed Original ResearchConceptsHBV/HDV infectionLiver complicationsAll-Payer Claims DatabaseClaims databaseRisk of liver-related morbidityHepatitis delta virus infectionPrevalence of HDVDelta virus infectionProportion of patientsTime of diagnosisLiver-related morbidityUS insured populationHDV prevalenceHBV populationsHIV infectionCompensated cirrhosisDecompensated cirrhosisHBV infectionDelayed DiagnosisHDV infectionHepatitis BViral hepatitisHBV/HDVPatient characteristicsSevere formPrevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis
Aghaei A, Gholami J, Sangchooli A, Rostam-Abadi Y, Olamazadeh S, Ardeshir M, Baheshmat S, Shadloo B, Taj M, Saeed K, Rahimi-Movaghar A. Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis. The Lancet Global Health 2023, 11: e1225-e1237. PMID: 37474230, DOI: 10.1016/s2214-109x(23)00267-x.Peer-Reviewed Original ResearchConceptsPrevalence of injection drug useInjection drug usePrevalence of HIVHepatitis B virusHepatitis C virusB virusC virusMeta-analysisSystematic reviewHepatitis C virus infection ratesEastern Mediterranean RegionCharacteristics of peopleDrug useHIV infection ratesOpioid agonist treatmentInfection rateProgramme servicesPopulation size of peopleHepatitis CAgonist treatmentHarm reduction servicesHepatitis BWHO Eastern Mediterranean RegionWeb of ScienceProvision of services554 RISK OF CIRRHOSIS AND HEPATOCELLULAR CARCINOMA ACROSS A GRADIENT OF BASELINE HEPATITIS B VIRAL LOAD AMONG A NATIONAL COHORT OF PREDOMINANTLY NON-ASIAN VETERANS WITH CHRONIC HEPATITIS B IN THE UNITED STATES
Yang Z, Cheung R, Lim J, Jou J, Wong R. 554 RISK OF CIRRHOSIS AND HEPATOCELLULAR CARCINOMA ACROSS A GRADIENT OF BASELINE HEPATITIS B VIRAL LOAD AMONG A NATIONAL COHORT OF PREDOMINANTLY NON-ASIAN VETERANS WITH CHRONIC HEPATITIS B IN THE UNITED STATES. Gastroenterology 2023, 164: s-1254. DOI: 10.1016/s0016-5085(23)03914-8.Peer-Reviewed Original ResearchProstate-specific antigen test in Brazilian indigenous: a cross-sectional study
Brito G, Marques M, da Silva A, de Lucia R, Croda J, Simionatto S. Prostate-specific antigen test in Brazilian indigenous: a cross-sectional study. Research Society And Development 2023, 12: e15412439395-e15412439395. DOI: 10.33448/rsd-v12i4.39395.Peer-Reviewed Original ResearchProstate cancerHepatitis BPSA valuesPreventive examinationsProstate-specific antigen valuesProstate-specific antigen (PSA) testMean PSA valueC virus infectionRapid testCross-sectional studyUrological symptomsTotal PSAAntigen testAntigen valuesMean ageCancer screeningClinical dataFamily historyVirus infectionPathophysiological correlationsCancerSociodemographic conditionsInfectionHIVSyphilisPrevalence of Genotypic Resistance Mutations in Patients with Chronic Hepatitis B (HBV) Treated with Entecavir and Tenofovir in Two Reference Centers in the North and Northeast of Brazil
Pacheco S, Schinoni M, Stocker A, Paraná R, Reis M, Silva L. Prevalence of Genotypic Resistance Mutations in Patients with Chronic Hepatitis B (HBV) Treated with Entecavir and Tenofovir in Two Reference Centers in the North and Northeast of Brazil. Medical Research Archives 2023, 11 DOI: 10.18103/mra.v11i3.3473.Peer-Reviewed Original ResearchGenotypic resistance mutationsResistance mutationsHepatitis BChronic hepatitis BFirst-line treatmentVaccine escape mutationsHepatitis B virusChronic HBVAntiviral treatmentLine treatmentLiver diseaseTherapeutic managementB virusEscape mutationsGenotypic resistanceReference centerPatientsGenetic mutationsEntecavirHBVTenofovirTreatmentNortheast of BrazilPresent studyNucleotide analogues
2022
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatmentDevelopment and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV
Kim HN, Nance RM, Re V, Silverberg MJ, Franco R, Sterling TR, Cachay ER, Horberg MA, Althoff KN, Justice AC, Moore RD, Klein M, Crane HM, Delaney JA, Kitahata MM. Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 89: 396-404. PMID: 35202048, PMCID: PMC8887786, DOI: 10.1097/qai.0000000000002886.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseLiver diseaseNorth American AIDS Cohort CollaborationStandardized medical record reviewAccessible clinical parametersHIV-specific factorsChronic hepatitis BFibrosis-4 indexMedical record reviewSpontaneous bacterial peritonitisHarrell's C-statisticHepatitis B virusHepatitis C virusAlcohol use disorderRisk prediction modelRace/ethnicityCohort CollaborationESLD riskHepatic impairmentVariceal bleedHepatitis BBacterial peritonitisHepatic encephalopathyRecord reviewClinical parametersRationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans
Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction Science & Clinical Practice 2022, 17: 6. PMID: 35101115, PMCID: PMC8802273, DOI: 10.1186/s13722-022-00286-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderVeterans Healthcare AdministrationFormulations of buprenorphineComparative effectiveness trialOpioid useEffectiveness trialUse disordersOpioid epidemicSublingual buprenorphine/naloxoneSevere opioid use disorderBuprenorphine/naloxoneUS opioid epidemicClinical effectiveness trialStandard of careEffective medication treatmentsExtended-release formulationUrgent clinical needLong-term trialsHepatitis BSecondary outcomesSevere sequelaeOpioid abstinencePrimary outcomeMedication treatmentTRIAL REGISTRATION
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply